Yahoo Finance

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
Nasdaq

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin ...

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
Nasdaq

Intellia: FDA Removes Clinical Hold On IND For MAGNITUDE Phase 3 Trial Of Nexiguran Ziclumeran

(RTTNews) - Intellia Therapeutics (NTLA) announced the FDA has removed the clinical hold on the Investigational New Drug application for the MAGNITUDE Phase 3 clinical trial of nexiguran ziclumeran ...
FierceBiotech

FDA fully releases clinical hold on Intellia CRISPR gene therapy trials

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death. The agency has ...
Pharmabiz

US FDA lifts clinical hold of Intellia Therapeutics’ MAGNITUDE phase 3 trial of nex-z for patients with transthyretin amyloidosis with cardiomyopathy

Intellia Therapeutics, Inc., a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, announced that the US Food and Drug ...